BioTime to Present at Two Upcoming Investor Conferences
September 06 2016 - 8:00AM
Business Wire
BioTime, Inc. (NYSE MKT: BTX), a clinical stage biotechnology
company with a focus on pluripotent stem cell technology, today
announced that it will be presenting at the following investor
conferences:
- 2016 Gateway Conference at the Four
Seasons Hotel, San Francisco, Wednesday, September 7, 2016, at
11:00am ET (8:00am PT)
- 18th Annual Rodman & Renshaw Global
Investor Conference at the Lotte New York Palace Hotel, New York
City, Tuesday, September 13, 2016, at 3:50pm ET (12:50pm PT)
Attendance at both conferences is by invitation only. BioTime’s
management will provide a corporate overview as well as an update
on its product development. Both presentations will be webcast live
and available for replay at the “Events & Presentations” page
of the “Investors & Media” section on BioTime’s website at
http://www.biotimeinc.com.
About BioTime
BioTime, Inc. is a clinical-stage biotechnology company focused
on developing and commercializing novel therapies developed from
what we believe to be the world’s premier collection of pluripotent
cell assets. The foundation of our core therapeutic technology
platform is pluripotent cells that are capable of becoming any of
the cell types in the human body. Pluripotent cells have potential
application in many areas of medicine with large unmet patient
needs, including various age-related degenerative diseases and
degenerative conditions for which there presently are no cures.
Unlike pharmaceuticals that require a molecular target, therapeutic
strategies based on the use of pluripotent cells are generally
aimed at regenerating or replacing affected cells and tissues, and
therefore may have broader applicability than pharmaceutical
products.
In addition to the development of therapeutics, BioTime’s
research and other activities have resulted, over time, in the
creation of other subsidiaries that address other non-therapeutic
market opportunities such as cancer diagnostics, drug development
and cell research products, and mobile health software
applications.
BioTime common stock is traded on the NYSE MKT and TASE under
the symbol BTX. For more information, please visit
www.biotimeinc.com or connect with the company on Twitter,
LinkedIn, Facebook, YouTube, and Google+.
To receive ongoing BioTime corporate communications, please
click on the following link to join our email alert list:
http://news.biotimeinc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160906005542/en/
BioTime, Inc.Dan L. Lawrence,
510-775-0510dlawrence@biotimeinc.comorInvestor Contact:EVC Group,
Inc.Michael Polyviou, 646-445-4800mpolyviou@evcgroup.comorMedia
Contact:Gotham Communications, LLCBill Douglass,
646-504-0890bill@gothamcomm.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2023 to Apr 2024